伏立康唑对血液病患者肺部侵袭性真菌感染的二级防护疗效分析

发布时间：2018-04-23 09:49

本文选题：伏立康唑 + 血液病　；参考：《中华医院感染学杂志》2017年11期

【摘要】：目的观察伏立康唑对血液病合并肺部侵袭性真菌感染的二级防护的疗效。方法选取医院血液科2011年1月-2016年4月收治52例恶性血液病患者,分为观察组与对照组,各26例,全部患者在化疗药物基础上,根据患者发病情况使用细胞集落因子、止血药物、常规抗真菌药物等支持药物治疗,观察组在上述治疗基础之上采用伏立康唑进行二级预防,治疗结束后观察两组患者预防成功率及不良反应,并比较两组患者干扰素伽玛(IFN-γ)及白介素-10(IL-10)表达水平。结果观察组患者预防成功率为86.96%,显著高于对照组61.90%,差异有统计学意义(P0.05);治疗前,两组患者IFN-γ、IL-10表达水平相当,差异无统计学意义;治疗后,观察组患者IFN-γ表达水平高于对照组,IL-10表达水平低于对照组,组间比较差异有统计学意义(P0.05);两组患者不良反应轻微,经对症治疗或停药后均予缓解,观察组患者总不良反应发生率为39.13%,对照组为9.52%,差异无统计学意义。结论伏立康唑用于血液病侵袭性真菌感染的预防有效且安全,疗效确切,耐受性较好,值得临床推广应用。
[Abstract]:Objective to observe the secondary protective effect of Volconazole on pulmonary invasive fungal infection in patients with hematologic diseases. Methods from January 2011 to April 2016, 52 patients with malignant hematological diseases were divided into two groups: the observation group and the control group. All patients were treated with cytokines on the basis of chemotherapeutic drugs. Hemostatic drugs, routine antifungal drugs and other supportive drugs were used to treat the patients in the observation group. The patients in the observation group were treated with voriconazole for secondary prevention on the basis of the above treatment. After the treatment, the success rate of prevention and the adverse reactions of the two groups were observed. The expression levels of interferon gamma (IFN- 纬) and interleukin-10 (IL-10) were compared between the two groups. Results the successful rate of prevention in the observation group was 86.96, which was significantly higher than that in the control group (61.90), the difference was statistically significant (P 0.05), the expression of IFN- 纬 IL-10 in the two groups was similar before treatment, and there was no significant difference between the two groups after treatment. The level of IFN- 纬 expression in the observation group was higher than that in the control group, and the level of IL-10 was lower than that in the control group, and the difference between the two groups was statistically significant (P 0.05). The incidence of total adverse reactions was 39.13 in the observation group and 9.52 in the control group. Conclusion Volconazole is effective and safe in the prevention of invasive fungal infection in hematological diseases.
【作者单位】：宁波市奉化区人民医院药剂科;宁波市奉化区人民医院血液肿瘤科;
【基金】：浙江省医药卫生一般研究计划基金资助项目(2016KYA016)
【分类号】：R519;R733

【相似文献】